Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat
Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 34,237,779 | $385,859,769 | -26% | 1.12% |
| 2. | QVT Financial Daniel Gold | 29,381,635 | $331,131,026 | -56% | 29.5% |
| 3. | Rubric Capital Management David Rosen | 20,370,336 | $229,573,687 | +15% | 3.47% |
| 4. | Two Seas Capital Sina Toussi | 10,598,040 | $119,439,911 | +5% | 2.01% |
| 5. | Anchorage Advisors Kevin Michael Ulrich And Anthony Davis | 4,832,642 | $54,463,875 | 21.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 4,000,000 | $20,000,000.00 | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | $33,635.46 | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | $121,318.70 | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.96 | 385,816 | $5,000,175.36 | 35,508,359 | 2025-09-05 | Filing | |
| $12.92 | 194,933 | $2,518,534.36 | 35,894,175 | 2025-09-04 | Filing | |
| $12.50 | 1,195,000 | $14,937,500.00 | 36,089,108 | 2025-09-03 | Filing | |
| $11.72 | 100,000 | $1,172,000.00 | 1,653,585 | 2025-08-20 | Filing | |
| $11.52 | 100,000 | $1,152,000.00 | 1,462,223 | 2025-07-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 59,952,652 | $675,666,388 | 5.36% | |
| 2. | 55,509,281 | $625,589,596 | 0.04% | |
| 3. | 44,693,966 | $503,701,008 | 0.03% | |
| 4. | 40,316,307 | $454,364,775 | 0.01% | |
| 5. | 39,326,336 | $443,207,807 | 0.01% |
News See All
7 Hot Healthcare Stocks to Buy Right Now
The majority of Americans have experienced the annoyance of having their health insurance rejected, frequently without any recourse after contacting carriers by email and phone. Dr.
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Roivant Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Why Roivant Sciences Ltd. (ROIV) Surged On Thursday
We recently published a list of While Wall Street Naps, These 10 Stocks Run Wild. In this article, we are going to take a look at where Roivant Sciences Ltd.
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
The reiteration comes after the company appointed the current President and COO of Roivant, Dr. Eric Venker as CEO of Immunovant. Roivant Sciences Ltd.
Hedge Fund Resource Center Billionaire Hedge Funds
